With the introduction of ICIs and BRAF/MEK targeted therapies, we and others have shown that the 5-year overall survival (OS) rate for patients with metastatic melanoma has risen from less than 10% to 30% to 50%.1,2. This evidence concerns the gene MAP2K7 and metastatic melanoma.